|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.44 | 89.46 | 104.56 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1177.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 26,920.30 | 26,687.60 | 23,908.20 | 35,474.40 | Total Expenditure | 22,103.40 | 21,235.80 | 19,684.40 | 28,556.10 | PBIDT (Excl OI) | 4,816.90 | 5,451.80 | 4,223.80 | 6,918.30 | Other Income | 3,311.30 | 670.80 | 948.80 | 2,881.70 | Operating Profit | 8,128.20 | 6,122.60 | 5,172.60 | 9,800.00 | Interest | 612.50 | 366.90 | 315.90 | 489.70 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 7,515.70 | 5,755.70 | 4,856.70 | 9,310.30 | Depreciation | 643.50 | 657.90 | 596.30 | 1,150.00 | Profit Before Tax | 6,872.20 | 5,097.80 | 4,260.40 | 8,160.30 | Tax | 634.40 | 1,301.30 | 1,080.40 | 1,712.30 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 6,237.80 | 3,796.50 | 3,180.00 | 6,448.00 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 6,237.80 | 4,157.40 | 3,359.50 | 6,448.00 | Equity Capital | 585.90 | 585.90 | 585.90 | 585.90 | Face Value (IN RS) | 1 | 1 | 1 | 1 | Reserves | | | | | Calculated EPS | 10.65 | 6.48 | 5.43 | 11.01 | Calculated EPS (Annualised) | 42.59 | 25.92 | 21.71 | 44.02 | No of Public Share Holdings | 282,223,138.00 | 282,223,138.00 | 282,223,138.00 | 282,223,138.00 | % of Public Share Holdings | 48.17 | 48.17 | 48.17 | 48.17 | | | | | | PBIDTM% (Excl OI) | 17.89 | 20.43 | 17.67 | 19.50 | PBIDTM% | 30.19 | 22.94 | 21.64 | 27.63 | PBDTM% | 27.92 | 21.57 | 20.31 | 26.25 | PBTM% | 25.53 | 19.10 | 17.82 | 23.00 | PATM% | 23.17 | 14.23 | 13.30 | 18.18 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|